AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
Mar 28, 2024
Live webcast presentation on Wednesday, April 3rd at 1:35 PM ETOCALA, Fla., March 28, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM ImmunoTech, will present at the...
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
Mar 26, 2024
OCALA, Fla., March 26, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") announced today that management will host a conference call and webcast to discuss the Company's Q4/FY2023 operational and financial results on Tuesday, April 2, 2024, at...
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
Mar 25, 2024
Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through AmpligenOCALA, Fla., March 25, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM") today announced the publication of new data analysis from a long-term...
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Mar 22, 2024
OCALA, Fla., March 22, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), today announced the next CEO Corner segment has been published on the Company's website. For the CEO Corner segment, Thomas Equels, Chief Executive Officer of AIM...
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Mar 20, 2024
OCALA, Fla., March 20, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), today announced the next CEO Corner segment has been published on the Company's website. For the CEO Corner segment, Thomas Equels, Chief Executive Officer of AIM...
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
Mar 15, 2024
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, March 20th at 12:00 PM ETOCALA, Fla., March 15, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), today announced that it will present at the Virtual...
AIM ImmunoTech Announces Launch of CEO Corner Platform
Mar 7, 2024
CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties the ability to ask questions and submit topics for future videos Access the AIM CEO Corner Here! OCALA, Fla., March 07, 2024 --...
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
Feb 29, 2024
Company continues progress across Ampligen® clinical development programs Growing body of promising data demonstrates Ampligen's potential to address multiple high-value indications OCALA, Fla., Feb. 29, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or...
AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
Feb 14, 2024
Phase 1b portion of the study expected to be completed within six monthsOCALA, Fla., Feb. 14, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced the first subject has been dosed at Erasmus Medical Center ("Erasmus MC") in a Phase...
AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
Feb 8, 2024
Efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions Safety results show Ampligen is generally well tolerated in the treatment of Post-COVID Conditions OCALA, Fla., Feb. 08, 2024 -- AIM ImmunoTech Inc....